Achillion Pharmaceuticals reports that the FDA has reviewed and cleared the Investigational New Drug Application for ACH-5228, the company’s second-generation oral factor D inhibitor.
The opening IND study in the United States will be a drug-drug interaction study with ACH-5228. The Company expects to begin a Phase 2 proof-of-concept paroxysmal nocturnal hemoglobinuria clinical trial of ACH-5228 in the first half of 2020. more